Regado garners $40M Series D for clotting tech

Regado Biosciences has pulled together a $40 million Series D round to push the development of a new technology designed to give doctors better control over blood clots. Edmond de Rothschild Investment Partners took the lead in the round, which was also backed by Domain Associates, Quaker Bioventures, Aurora Funds, Caxton Advantage Life Sciences Fund and other individual investors.

Basking Ridge, NJ-based Regado will use the money to pursue a new therapeutic approach to blood clots originally licensed from Duke University. Using a paired aptamer-control agent technology, its researchers believe REG1 can give physicians a tool to manage coagulation, ‘dialing' the anticoagulation effect up or down as doctors try to fight harmful clots while encouraging healing clots. The biotech released positive results from a Phase IIa clinical trial of REG1 at the European Society of Cardiology Congress at the end of August.

"Regado has a comprehensive antithrombotic pipeline, which reflects the company's expertise in the discovery and development of therapeutic aptamers with active control agents for application in the areas of both arterial and venous thrombosis," said CEO David Mazzo.

- here's Regado's release

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.